TrialA Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa
Trial details
- Registry ID
- NCT04917874
- Phase
- Phase 3
Drug research
Open Label Topical Beremagene Geperpavec (B-VEC)
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Long-term Treatment With B-VEC for Dystrophic Epidermolysis BullosaNCT04917874 | KRYS | Phase 3 | Completed | 2023-07-31Actual |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |